Tildacerfont for the treatment of patients with classic congenital adrenal hyperplasia: results from a 12-week phase 2 clinical trial in adults with classic CAH

TY - JOUR

T1 - Tildacerfont for the treatment of patients with classic congenital adrenal hyperplasia: results from a 12-week phase 2 clinical trial in adults with classic CAH

AU - Auchus, Richard

AU - Merke, Deborah

AU - Ivy-Joan, Madu

AU - Nakhle, Samer

AU - Sarafoglou, Kyriakie

AU - Huang, Michael

AU - Moriarty, David

AU - Barnes, Chris

AU - Newfield, Ron

N1 - 1University of Michigan, USA; 2Eunice Kennedy Shriver National Institute of Child Health and Human Development, USA; 3Diabetes Associates Medical Group, USA; 4Palm Medical Group, USA; 5University of Minnesota Medical School, USA; 6Former employee of Spruce Biosciences, Inc., USA; 7Spruce Biosciences, Inc., USA; 8 University of California San Diego, USA Background Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder characterized by insufficient cortisol production resulting in excess adrenocorticotropic hormone (ACTH) and adrenal androgen production.

PY - 2021/5/15

Y1 - 2021/5/15

UR - https://www.endocrine-abstracts.org/ea/0073/ea0073pep1.2

U2 - 10.1530/ENDOABS.73.PEP1.2

DO - 10.1530/ENDOABS.73.PEP1.2

M3 - Article

VL - 73

JO - 23rd European Congress of Endocrinology (ECE 2021)

JF - 23rd European Congress of Endocrinology (ECE 2021)

ER -